---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-22-008134"
form_type: "8-K"
ticker: "PGEN"
cik: "0001356090"
company_name: "PRECIGEN, INC."
filed_at: "2022-05-09T23:59:59+00:00"
generated_at: "2026-06-25T22:17:50.005504+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Precigen Q1 revenue $32M (+31% YoY); Fast Track for PRGN-3006 in AML

## Summary
- Total revenues $32.0M, up 31% vs $24.5M YoY; net loss $19.3M ($0.10/share).
- Cash, equivalents, short- & long-term investments $142.1M as of March 31, 2022.
- FDA Fast Track designation for PRGN-3006 UltraCAR-T in relapsed/refractory AML.
- Phase 2 study for PRGN-2012 in RRP dosed first patient; Phase 1b expansion arm for PRGN-3006 initiated.
- R&D expenses rose $2.2M (+21%) driven by clinical/preclinical program advancement.

## SEC filing metadata
- accession: 0000950103-22-008134
- form_type: 8-K
- ticker: PGEN
- cik: 0001356090
- company_name: PRECIGEN, INC.
- filed_at: 2022-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356090/000095010322008134/0000950103-22-008134-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356090/000095010322008134/dp172815_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-22-008134
- JSON: https://secwatch.observer/filing/0000950103-22-008134.json
- Plain text: https://secwatch.observer/filing/0000950103-22-008134.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.